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INTRODUCTION 
 
 
         Among all the neurological diseases of adult life, the cerebrovascular 
ones clearly rank the first in frequency and importance. Atleast 50% of the 
neurological disorders in a general hospital are of this type. Stroke, after heart 
disease and cancer is the most common cause of death. In the developed 
countries among 700000 cases of stroke, roughly 600000 are ischemic 
lesions. All the physicians have a role to play in the prevention of stroke by 
encouraging the reduction in risk factors(1). Stroke also entails a high socio 
economic burden due to increased morbidity and mortality(2).Ischemic 
strokes account for > 80% of total stroke events. Early identification of 
individuals at risk could be of help in primary prevention strategies(3). 
 
           UA is the most abundant aqueous antioxidant in humans, and 
contributes as much as two-thirds of all free radical scavenging capacity in 
plasma. It is particularly effective in quenching hydroxyl, superoxide and 
peroxynitrite radicals, and may serve a protective physiological role by 
preventing lipid peroxidation(34). In a variety of organs and vascular beds, 
local UA concentrations increase during acute oxidative stress and ischaemia, 
and the increased concentrations might be a compensatory mechanism that 
confers protection against increased free radical activity (64). In animal 
models, local UA concentrations significantly increase in acute brain 
  
injury(62).For example, in the rat, middle cerebral artery occlusion causes a 
significant increase in cerebral UA concentrations, which can persist for 
several days after the injury(63). These observations have prompted interest in 
the potential impact of raised local UA concentrations in the setting of acute 
ischaemic stroke.  
           
           The role of  serum uric acid (SUA) levels as an independent risk factor 
for vascular disease has been questioned for decades(4). Evidence from 
epidemiological studies suggest that the elevated SUA levels may predict an 
increased risk for cerebrovascular (CV) events including stroke (4-7). 
Moreover therapeutic modalities with a SUA lowering potential have been 
shown to reduce CV disease morbidity and mortality (8). 
 
         Subjects with NIDDM  have a two fold to four fold greater risk of all 
manifestations of atherosclerotic vascular disease including stroke (10). The 
increased risk of stroke is only partly explained by the adverse effects of 
NIDDM on classic risk factors or risk factors clustering with 
hyperinsulinemia(10). SUA has been recently associated with insulin 
resistance(11).One study (10) indicates that hyperuricemia is a strong 
predictor of stroke events in middle aged patients with NIDDM independent 
of other CV  risk factors. 
                          
  
         Although high SUA levels have been identified as an important risk 
factor for stroke in unselected populations in a number of epidemiological 
studies (4-7), it is unclear whether high SUA levels promote or protect against 
the development of CV disease or simply acts as a passive or circumstantial 
marker of increased risk(12). However data from larger studies (NHANES I) 
have established an independent association in subjects older than 45, 
regardless of confounding factors such as sex, menopausal status , diuretic 
use, presence of  CV disease or race(13). 
 
            In this respect SUA levels could be used as an easy to measure serum 
marker in selecting and appropriately treating subjects at risk(9). 
 
 
 
 
 
 
 
 
 
 
 
  
REVIEW OF LITERATURE 
 
URIC ACID(16) 
 
Background 
Uric acid is the final product of purine metabolism in human beings. 
Despite the fact that uric acid was first identified approximately 2 centuries 
ago, certain pathophysiologic aspects of hyperuricemia are still not clearly 
understood. For years, hyperuricemia has been identified with or thought to 
be the same as gout, but uric acid has now been identified as a marker for a 
number of metabolic and hemodynamic abnormalities. 
 
Unlike allantoin, the more soluble end product found in lower animals, 
uric acid is a poorly soluble end product of purine metabolism in humans. 
Human beings have higher levels of uric acid, in part, because of a deficiency 
of the hepatic enzyme, uricase, and a lower fractional excretion of uric acid. 
Approximately two thirds of total body urate is produced endogenously, while 
the remaining one third is accounted for by dietary purines. Approximately 
70% of the urate produced daily is excreted by the kidneys, while the rest is 
eliminated by the intestines. However, during renal failure, the intestinal 
contribution of urate excretion increases to compensate for the decreased 
elimination by the kidneys. 
 
  
The blood levels of uric acid are a function of the balance between the 
breakdown of purines and the rate of uric acid excretion. Theoretically, 
alterations in this balance may account for hyperuricemia, although clinically 
defective elimination accounts for most cases of hyperuricemia. 
 
Pathophysiology 
Uric acid in the blood is saturated at 6.4-6.8 mg/dL at ambient 
conditions, with the upper limit of solubility placed at 7 mg/dL. Urate is 
freely filtered at the glomerulus, reabsorbed, secreted, and then again 
reabsorbed in the proximal tubule. The recent cloning of certain urate 
transporters will facilitate the understanding of specific mechanisms by which 
urate is handled in the kidney and small intestines.  
 
A urate/anion exchanger (URAT1) has been identified in the brush-
border membrane of the kidneys and is inhibited by an angiotensin II receptor 
blocker, losartan. A human organic anion transporter (hOAT1) has been 
found to be inhibited by both uricosuric drugs and antiuricosuric drugs, while 
another urate transporter (UAT) has been found to facilitate urate efflux out of 
the cells. These transporters may account for the reabsorption, secretion, and 
reabsorption pattern of renal handling of urate. 
 
  
Urate secretion does appear to correlate with the serum urate 
concentration because a small increase in the serum concentration results in a 
marked increase in urate excretion. 
 
Hyperuricemia may occur because of decreased excretion 
(underexcretors), increased production (overproducers), or a combination of 
these two mechanisms. 
 
Underexcretion accounts for most causes of hyperuricemia. Urate 
handling by the kidneys involves filtration at the glomerulus, reabsorption, 
secretion, and, finally, postsecretory reabsorption. Consequently, altered uric 
acid excretion can result from decreased glomerular filtration, decreased 
tubular secretion, or enhanced tubular reabsorption. While decreased urate 
filtration may not cause primary hyperuricemia, it can contribute to the 
hyperuricemia of renal insufficiency. Decreased tubular secretion of urate 
occurs in patients with acidosis (eg, diabetic ketoacidosis, ethanol or 
salicylate intoxication, starvation ketosis). The organic acids that accumulate 
in these conditions compete with urate for tubular secretion. Finally, enhanced 
reabsorption of uric acid distal to the site of secretion is the mechanism 
thought to be responsible for the hyperuricemia observed with diuretic 
therapy and diabetes insipidus. 
 
  
Overproduction accounts for only a minority of patients presenting 
with hyperuricemia. The causes for hyperuricemia in overproducers may be 
either exogenous (diet rich in purines) or endogenous (increased purine 
nucleotide breakdown). A small percentage of overproducers have enzymatic 
defects that account for their hyperuricemia. These include a complete 
deficiency of hypoxanthine guanine phosphoribosyltransferase (HGPRT) as 
in Lesch-Nyhan syndrome, partial deficiency of HGPRT (Kelley-Seegmiller 
syndrome), and increased production of 5-phospho-alpha-d-ribosyl 
pyrophosphate (PRPP) activity. Accelerated purine degradation can result 
from rapid cell proliferation and turnover (blast crisis of leukemias) or from 
cell death (rhabdomyolysis, cytotoxic therapy). Glycogenoses types III, IV, 
and VII can result in hyperuricemia from excessive degradation of skeletal 
muscle ATP. 
 
Combined mechanisms (underexcretion and overproduction) can also 
cause hyperuricemia. The most common cause under this group is alcohol 
consumption, which results in accelerated hepatic breakdown of ATP and the 
generation of organic acids that compete with urate for tubular secretion. 
Enzymatic defects such as glycogenoses type I and aldolase-B deficiency are 
other causes of hyperuricemia that result from a combination of 
overproduction and underexcretion. 
 
  
New findings revealed that urate crystals can engage an intracellular 
pattern recognition receptor, the macromolecular NALP3 (cryopyrin) 
inflammasome complex. NALP3 inflammasome may result in interleukin 1 
(IL-1) beta production, which, in turn, incites an inflammatory response. 
Inhibition of this pathway has the potential to be targeted for hyperuricemia-
induced crystal arthritis.  
 
Frequency 
  A Japanese study that used an administrative claims database to 
ascertain 10-year trends in the prevalence of hyperuricemia concluded that the 
prevalence of hyperuricemia in the overall study population increased during 
the 10-year follow-up. When stratified by age, the prevalence increased 
among groups older than 65 years in both sexes. In those younger than 65 
years, men had a prevalence 4 times higher than that in women, but in those 
older than 65 years, the gender gap narrowed to 1:3 (female-to-male ratio) 
with gout and/or hyperuricemia. 
 
Mortality / Morbidity 
Hyperuricemia has been associated with increased morbidity in 
patients with hypertension and is associated with increased mortality in 
women and elderly persons. The cause for this is unknown, but hyperuricemia 
  
is probably a marker for comorbid risk factors rather than a causative factor, 
per se. 
 
Race 
A high prevalence of hyperuricemia exists in indigenous races of the 
Pacific, which appears to be associated with a low fractional excretion of uric 
acid. African American persons develop hyperuricemia more commonly than 
white persons. 
 
Sex 
Hyperuricemia, and particularly gouty arthritis, are far more common 
in men than in women. Only 5% of patients with gout are female, but uric 
acid levels increase in women after menopause. 
 
Age 
The normal serum uric acid level is lower in children than in adults. 
The upper limit of the reference range for children is 5 mg/dL (0.30 mmol/L). 
The upper limit of the reference range for men is 7 mg/dL (0.42 mmol/L) and 
for women is 6 mg/dL (0.36 mmol/L). The tendency to develop 
hyperuricemia increases with age 
 
  
Sources of uric acid 
In many instances, people have elevated uric acid levels for hereditary 
reasons. Diet may also be a factor. 
 
Purines are found in high amounts in animal food products, especially 
internal organs. 
 
Examples of high purine sources include: sweetbreads, anchovies, 
sardines, liver, beef kidneys, brains, meat extracts (e.g Oxo, Bovril), herring, 
mackerel, scallops, game meats, and gravy. 
 
A moderate amount of purine is also contained in beef, pork, poultry, 
fish and seafood, asparagus, cauliflower, spinach, mushrooms, green peas, 
lentils, dried peas, beans, oatmeal, wheat bran and wheat germ. Moderate 
intake of purine-containing food is not associated with an increased risk of 
gout.] 
 
Serum uric acid can be elevated due to high fructose intake, reduced 
excretion by the kidneys, and  high intake of dietary purine. 
 
Fructose can be found in processed foods and soda beverages - in some 
countries, in the form of high fructose corn syrup. 
  
Anti-oxidant capacity 
Uric acid may be a marker of oxidative stress(17), and may have a 
potential therapeutic role as an antioxidant. On the other hand, like other 
strong reducing substances such as ascorbate, uric acid can also act as a 
peroxidant(18), particularly at elevated levels. Thus, it is unclear whether 
elevated levels of uric acid in diseases associated with oxidative stress such as 
stroke and atherosclerosis are a protective response or a primary 
cause(19).For example, some researchers propose that hyperuricemia-induced 
oxidative stress is a cause of metabolic syndrome(20). On the other hand, 
plasma uric acid levels correlate with longevity in primates and other 
mammals(17). This is presumably a function of urate's antioxidant properties 
 
  
 
 
 
 
 
 
                                          
  
STROKE(68) 
 
                         
A  Stroke (STRUCK BY THE HAND OF GOD) or cerebrovascular 
accident (CVA) is defined by the abrupt onset of neurological deficit that is 
attributable to a focal vascular cause. The clinical manifestations of stroke are 
highly variable because of the complex anatomy of brain and its vasculature. 
                            
        Cerebral ischemia is caused by a reduction in blood flow that lasts longer 
than several seconds. Neurological symptoms are manifest within seconds 
because neurons lack glycogen, so energy failure is rapid. When blood flow is 
quickly restored, brain tissue can recover fully and the patient’s symptoms are 
only transient, that is called Transient Ischemic Attack(TIA).Typically the 
neurological signs and symptoms of a TIA lasts for 5 to 15 min but by 
definition must last for < 24 hrs. If the cessation of flow lasts for more than a 
few minutes, infarction or death of brain tissue results. Stroke has occurred if 
the neurological signs and symptoms last for > 24 hrs. 
 
         Focal ischemia or infarction is usually caused by thrombosis of cerebral 
vessels themselves or by emboli from a proximal arterial source or the heart. 
Cerebral hemorrhage produces neurological symptoms by producing a mass 
effect on neural structures or from toxic effects of  blood itself. 
 
 
  
CEREBRAL BLOOD FLOW (68) 
 
                     
• Gray matter -75 ml / 100 gm / min 
• White matter – 30 ml / 100 gm /min 
• Oxygen consumption ---  3.5 ml / 100 gm / min 
• Glucose utilization  ---- 5 mg / 100 gm / min 
 
             Brain store of glucose lasts only for 2 min after cessation of blood 
flow. The oxygen stores lasts only for 8 to 10 sec after cessation of blood 
flow. 
 
           A fall in blood flow to zero causes death of brain tissue within 4 to 10 
min. Tissue surrounding the core region of infarction is ischemic but 
reversibly  dysfunctional and is referred as ischemic penumbra. The ischemic 
penumbra will eventually infarct if no change in flow occurs and hence saving 
the ischemic penumbra is the goal of  thrombolytic therapy. 
 
 
 
 
 
 
  
RISK FACTORS FOR STROKE 
 
 
MAJOR RISK FACTORS( 14 ): 
THE most important established risk factor for stroke is AGE , and 
second is probably HYPERTENSION. Additional well established risk 
factors are 
 
1. Gender ( male > female )                  7. Carotid bruits 
2. Family history                                    8. Smoking 
3. Diabetes mellitus                               9. Increased haematocrit 
4. Cardiac disease                                  10. Elevated fibrinogen level  
5.  Prior stroke                                       11. Haemoglobinopathy 
6.Transient Ischemic attacks                  12. Drug abuse such as cocaine 
 
OTHER RISK FACTORS (15 ) : 
 
1.Hyperlipidemia          
2. Diet                           
3. Oral contraceptives  
4. Sedentary life style. 
5. Obesity                                  
 6. Peripheral vascular disease   
 7. HYPERURICEMIA             
 8. Infections. 
9.Homocystinemia 
10. Migraine 
11.Race     
12. Geographic location 
13. Season and climate 
14.Type A personality 
15. Alcohol consumption 
  
Clinical presentation  
Stroke should be considered in any patient presenting with an acute 
neurological deficit (focal or global) or altered level of consciousness. 
Patients' symptoms vary depending on the area of the brain affected and the 
extent of the damage.  
 
.     No features of the history can accurately distinguish between ischaemic 
and haemorrhagic stroke. But haemorrhagic stroke is perhaps more likely if 
the presentation includes features of raised intracranial pressure (such as 
nausea, vomiting, and headache). Seizures are also more common in 
hemorrhagic stroke than in ischaemic stroke, occurring in up to 28% of 
hemorrhagic strokes. Meningism, the symptoms of meningeal irritation 
associated with acute febrile illness or dehydration without actual infection of 
the meninges, may also result from blood in the ventricles after a haem- 
orrhagic stroke. Four important stroke syndromes are caused by disruption of 
particular cerebrovascular distributions.  
 
Anterior cerebral artery   
This primarily affects frontal lobe function, which results in altered 
mental status, contralateral lower limb weakness and hypoaesthesia, and gait 
disturbance.  
 
  
Middle cerebral artery 
This commonly results in contralateral hemiparesis, contralateral 
hypoaesthesia, ipsilateral hemianopia, and gaze preference toward the side of 
the lesion. Agnosia, a loss in ability to recognise objects, persons, sounds, 
shapes or smells, in the absence of a specific sensory deficit or memory loss, 
is common.  
 
Receptive or expressive aphasia may result if the lesion occurs in the 
dominant (mainly left) hemisphere. Neglect (behaviour as if the contralateral 
sensory space does not exist) may result when the lesion occurs in the parietal 
cortex.  
 
Posterior cerebral artery 
This affects vision and thought, producing homonymous hemianopia, 
cortical blindness, visual agnosia, altered mental status, and impaired 
memory.  
 
Vertebrobasilar artery 
It causes a wide variety of cranial nerve, cerebellar, and brainstem 
deficits. These include vertigo, nystagmus, diplopia, visual field deficits, 
dysphagia, dysarthria, facial hypoaesthesia, syncope, and ataxia. Loss of pain 
and temperature sensation occurs on the ipsilateral face and contralateral 
body.  
  
PATHOPHYSIOLOGY OF STROKE(1) 
 
             
Cerebral infarction basically comprises two pathophysiologic processes. 
1. Loss in the supply of oxygen and glucose secondary to vascular 
occlusion. 
2. array of  cellular metabolism consequent to the collapse of energy 
producing processes ultimately with disintegration  of cell 
membranes.  
 
Vascular Factors :  
In several animal species including macaque monkeys and gerbils the 
critical level of cerebral blood flow was 23 ml / 100 gm / min ; if, after short 
periods time ,CBF is restored to higher levels the impairment of function can 
be reversed . Reduction of CBF below 10 to 12 ml /100 gm / min causes 
infarction regardless of duration. The critical level of hypoperfusion that 
abolishes function and leads to tissue damage is therefore a CBF between 12 
to 23 ml /100 gm / min . At this level EEG is slowed and below this level it 
becomes isoelectric . These biochemical abnormalities are reversed if the 
circulation is restored to normal level. Disturbance of calcium ion 
homeostasis and accumulation of free fatty acids interfere with full recovery. 
A CBF of 6 to 8 ml /100/gm /min causes marked ATP depletion, increase in 
extra cellular K+ increase in intracellular calcium and cellular acidosis, 
  
leading invariably to histological signs of necrosis. Free fatty acids are 
activated and destroy the phospholipids of neuronal membranes. 
Prostoglandins, leucotrienes and free radicals accumulate and intracellular 
proteins and enzymes are denatured. 
 
         Penumbra zone exists at the margin of an infarction ,but not all, and the 
degree of irreversible tissue damage is difficult to determine. The neurons in 
the pneumbra are considered to be “stunned” by moderate ischemia and 
subject to salvage if blood flow is restored in a certain period of time. As with 
infarction , the duration of ischemia plays a role. Some studies show that 
elevating the systolic blood pressure or improving the rheological flow 
properties of blood in small blood vessels by haemodilution improves flow in 
the penumbra, however with mixed success. 
 
Metabolic Factors:  
           Excitatory neurotransmitters , particularly glutamate and aspartate , 
which are formed from glycolytic intermediates of the Kreb’s cycle, released 
by ischemic cells excite neurons and produce an influx of Na+ and Ca2+ , lead 
onto irreversible cell injury. This is currently a subject of active biochemical 
and clinical research. Additional biochemical events must be induced by 
ischemia, including the production of free radicals, which leads to 
peroxidation and disruption of the outer cell membrane. Clearly these cascade 
  
of cellular events that lead to neuronal death is likely to be more complex than 
is currently envisioned. 
 
           However , the extent of neural tissue dysfunction is not dictated solely 
by the activation of these mechanisms in neurons. It is now clear that highly 
toxic influences are exerted on oligodendroglial cells in white matter during 
ischemia. Moreover , injury to both neurons and oligodendroglial cells in 
brain tissue is augmented by an inflammatory response to the initial injury, 
activating endothelial cells to express cell adhesion molecules that can attract 
additional inflammatory cells and up regulating  levels of inflammatory 
proteases (eg..metalloproteases)and cytokines (eg. interleukins and 
chemokines ). 
 
CT Scan And Ischaemic Stroke 
Within six hours of the onset of ischaemic stroke, most patients will 
have a normal computed tomography scan. After 6-12 hours, sufficient 
oedema may collect into the area of the stroke so that a region of hypo- 
density may be seen on the scan.  
 
 
 
 
  
Radiological clues before this include:  
• Insular ribbon sign (loss of definition of grey-white interface in the 
lateral margins of the insula due to oedema in the insular cortex; (fig 1)   
• Hyperdense middle cerebral artery sign (fig 2)  
• Hypoattenuation in the lentiform nucleus (fig 3)  
• Sulcal obliteration  
• Shifting due to oedema  
• Loss of grey-white matter differentiation.  
 
These are all due to an increasing level of oedema in the brain, 
however, they rely on a high level of expertise of the radiologist and are often 
not present. Computed tomography scans also may fail to show some 
parenchymal haemorrhages smaller than 1 cm as a result of low resolution. 
 
 
                        
 
 
 
 
 
 
  
Fig. 1 : Computer tomograph after ischaemic stroke, showing oedema in 
insular cortex, as shown by solid arrows (open arrows show normal side ) 
                                        
 
 
Fig . 2. Computed tomograph after ischaemic stroke, showing hyperdense 
middle cerebral artery sign. 
   
 
  
Fig .3. Computed tomograph after ischaemic stroke, showing 
hypoattenuation in the lentiform nucleus, as shown by solid arrows (open 
arrows show normal side). 
 
   
 
  
SUA AND PATHOGENESIS OF STROKE 
 
How UA may play a pathogenic role in stroke could be explained by 
experimental evidences. The possible mechanisms are as under. 
 
SUA AND HYPERTENSION:  
1. Elevated SUA level is an independent predictor of  hypertension in 25 
% of patients with new onset , untreated primary hypertension.(21) 
2. The increase in SUA level may be caused by the decreased  renal blood 
flow that usually accompanies the hypertensive state , because low renal 
blood flow stimulates urate reabsorbtion .(22) 
3. Experimentally induced hyperuricemia also increased the blood pressure 
in rats by a renal mechanism linked to inhibition of nitric oxide (NO), 
activation of rennin- angiotensin system, and development of renal 
arteriosclerosis(23). Once the renal arteriosclerosis develops, the kidney 
plays a major role in the maintenance of hypertension, and lowering the 
UA is no longer protective.(24) 
4. Prolonged hyperuricemia in rats also caused progressive renal injury via 
crystalline- independent mechanism (23) and accelerated established 
renal disease(25). 
  
5. Finally UA stimulated synthesis of monocyte chemoattractant protein-1 
by rat vascular smooth muscle cells(26) and this is known to stimulate 
macrophage infiltration of atherosclerotic vessels(27).  
 
SUA AND FREE RADICAL MEDIATED OXIDATIVE DAMAGE – 
CEREBRAL ISCHEMIA 
1. Cerebral infarction initiates a complex cascade of metabolic events in 
the surrounding tissue and free-radical-mediated oxidative damage plays 
a key role in the pathogenesis of cerebral ischemia (28). Free radicals 
are liberated from a variety of sources, including inflammatory cells, 
dysfunctional mitochondria and excitotoxic mechanisms stimulated by 
increased glutamate and aspartate concentrations(29) 
2. Hydroxyl radicals, peroxynitrite and superoxide, are powerful radicals 
that can cause lipid peroxidation, a self –propagating chain reaction that 
irreversibly damages plasma and mitochondrial membranes(30). 
Products of lipid peroxidation irreversibly disrupt enzymes, receptors, 
and membrane transport mechanisms. The generation of local oxidants 
augments local injury and increases infarct size(28). 
3. UA is the most abundant aqueous antioxidant in humans and may serve 
a  protective physiologic  role by preventing lipid peroxidation(34). It 
might therefore be expected  that having elevated SUA levels  during a 
stroke would be beneficial. Stroke is associated with a rapid decrease in 
  
serum antioxidants(31,32) and patients with lower plasma antioxidants 
at the time of acute stroke have a poorer outcome(33). However, only 
one study has reported that high SUA levels may be neuroprotective in 
patients with acute stroke(35), three other large series  found the 
opposite(6,7,9). 
                                         
           One explanation would be that UA, being an aqueous antioxidant, can 
become a pro-oxidant under certain circumstances, particularly if other 
antioxidants, such as ascorbate are low(36). Thus in patients with acute stroke 
the fall in ascorbate level could predispose the SUA to take on pro-oxidant 
properties. Consistent with this hypothesis is the observation that in acute 
stroke, those with high SUA and low ascorbate levels have the worst 
outcome(37).  
 
SUA AND ENDOTHELIAL DYSFUNCTION: 
             Different studies support the hypothesis that hyperuricemia causes 
vascular disease via endothelial dysfunction. For example, direct infusion of 
UA into the human brachial artery caused endothelial dysfunction(38). UA 
was also found to promote LDL-C oxidation in vitro (39) and to stimulate 
granulocyte adherence to the endothelium(40). 
 
  
            In addition, a consistent relationship between elevated SUA levels and 
circulating inflammatory markers has been reported (41-43). Moreover UA 
may accumulate as crystals within atherosclerotic plaques(44).  
           
SUA AND METABOLIC SYNDROME ( Met S ): 
SUA might increase the risk of developing stroke through its 
association with the Met S (45,46). SUA levels are often increased in subjects 
with Met S (47-49). 
 
1. Insulin Resistance (IR ) is probably the underlying condition 
triggering the development of both hyperuricemia and Met S  and  it 
is directly related to SUA levels(45,50). 
2. In patients with Met S, IR and decreased  insulin-induced UA 
excretion may account for the observed increase in UA level(45). 
3. IR may also be linked to purine biosynthesis and turnover with its 
attendant increase in UA levels(45,50). 
4. SUA may promote or worsen IR possibily through its ability to 
disturb endothelial function and thus inhibit NO bioavailability 
(38).Because insulin requires NO to stimulate glucose uptake, it has 
been hypothesized that hyperuricemia may have a key role in the 
pathogenesis of IR (51). 
  
5. In addition , a strong relationship between hyperuricemia and the 
risk factors of  Met S has been shown in recent large 
epidemiological studies (48,52). Furthermore, Met S  has recently 
been shown to represent a strong independent risk factor for 
ischemic stroke (53-56). 
6. The prognostic value of increased SUA levels was independent of 
all the other criteria of Met S, pointing to a direct link between SUA 
levels and adverse outcome in acute stroke (57). 
 
REDUCTION OF SUA AND PROTECTION AGAINST STROKE: 
           Beyond xanthine oxidase inhibitors like allopurinol and other 
uricosuric drugs (probenecid ,sulfinpyrazone), several other agents can 
decrease the SUA level, such as losartan and fenoifbrate (58). More 
importantly administration of statins significantly reduces SUA levels (59)  
and preserves renal function (60) and these actions independently protect 
against vascular events in high risk patients (49). Thus a reduction in SUA 
level could also partially explain the beneficial effects of statins against stroke 
(61). 
 
          The findings of LIFE study (Losartan Intervention for Endpoint 
Reduction in hypertension study) suggest that a decrease in SUA  induced by 
losartan treatment attenuates CV risk, including stroke (8).  
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AIMS OF THE STUDY 
 
 
 
  
AIMS OF THE STUDY 
 
 
The study is conducted to study the association  between Serum Uric 
Acid (SUA) and acute ischaemic nonembolic  stroke and to assess  its  risk 
factor potential using statistical  analysis. 
 
To also study the association between Serum Uric Acid (SUA) and 
other risk factors namely hypertension, Diabetes mellitus, CAD and adverse 
lipid profile.  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
MATERIALS AND 
METHODS 
 
  
MATERIALS AND METHODS 
 
 
INCLUSION  CRITERIA : 
1. Patients who were admitted in our hospital with first-ever-in 
life time acute ischaemic nonembolic stroke with or without 
CT Scan evidence of infarction  within 24 hrs of onset of 
stroke 
 
EXCLUSION  CRITERIA  :         
1. Patients with previous history of TIA / CVA 
2. Patients who are on thiazide diuretics 
3. Patients who are known cases of gout or show clinical 
evidences of gout. 
4. Patients with chronic renal failure 
5. Patients whose CT scan show haemorrhage or other space 
occupying lesions  other than infarct. 
6. Patients who were of known cardiac diseases which could be 
sources of emboli or whose echocardiogram shown sources 
of emboli. 
7. Patients with haemotological abnormalities like leukemia or 
other myeloproliferative disorders. 
 
  
A total of  100 patients ( 50 males and 50 females ) with acute stroke 
who met the criteria , admitted in GRH , MMC, Madurai from 01. 01 .2007 to 
31. 10. 2007 were randomly selected and included in this study. 
 
All subjects gave informed consent and the study protocol was 
approved by the  Ethical Committee. 
 
The blood samples were taken within 24 hrs of onset of stroke and sent 
for biochemical analysis and were analyzed in our Biochemical Laboratory 
using standard analyzer. The patients were further evaluated for the presence 
of additional risk factors as follows, using the below mentioned parameters. 
 
1. HYPERTENSION :  
a) known case of hypertension  
b) Blood pressure more than 140 mm of hg systolic and / or more 
than 90 mm of hg diastolic (62) 
                               
2. DIABETES MELLITUS:  
a) known case of diabetes mellitus  
b) random or postprandial blood sugar more than 200 mgs /dl  and 
/ or fasting blood sugar more than 125 mgs /dl(63) 
  
c) The patients with blood sugar values of IFG or IGT  were not 
included as diabetics in this study. 
 
3. CORONARY ARTERY DISEASE : 
Patients with ECG evidence of old infarction or                            
Echocardiogram showing regional wall motion abnormalities. 
 
4. ADVERSE LIPID PROFILE(64) : 
• Total cholesterol - more than 200 mgs/dl 
• Triglycerides   -    more than  150 mgs/dl 
• LDL-C              -  more than  130 mgs/dl 
• HDL-C              -  less than  40 mgs/dl 
 
5. SMOKING AND ALCOHOLISM: 
History of smoking and alcoholism within the last 5 yrs have been 
taken as smokers and alcoholics. 
 
Statistical Tools  
 The information collected regarding all the selected cases were 
recorded in a Master Chart. Data analysis was done with the help of computer 
using Epidemiological Information Package (EPI 2002). 
  
  
Using this software, frequencies, percentage, mean, standard deviation, 
x2 and  'p' values were calculated. A 'p' value less than 0.05 is taken to denote 
significant relationship.  
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OBSERVATIONS AND RESULTS 
 
 
           The observations made in this study are categorized, analysed and 
tabulated as under: 
 
1. AGE DISTRIBUTION :  
In this prospective study, 41 to 84 yrs old patients are included.   
  
Table 1.1 : Age Distribution 
 
Cases Age in years 
No % 
Less than 40 - - 
41- 49 19 19 
50 – 59 26 26 
60 – 69 35 35 
70 – 79 16 16 
80 & above  4 4 
Total 100 100 
Mean 
S.D 
59.8 yrs 
10.6 
  
Majority of this stroke population are between 50 to 69 yrs old, (61 % 
of the population ) with 33 Males and 28 females. The elderly population, 
  
above 70 yrs old constitute 20 % of the population with 9 males and 11 
females.  
 
Table 1.2 : Age Distribution according to sex 
 
Cases 
Males Females 
Age in years 
No. % No. % 
Less than 40 - - - - 
41- 49 8 16 11 22 
50 – 59 20 40 6 12 
60 – 69 13 26 22 44 
70 – 79 7 14 9 18 
80 & above  2 4 2 4 
Total 50 100 50 100 
Mean 
S.D 
59.1 
10.2 
60.5 
11.1 
‘p’ 0.2924 
Not significant 
 
The mean age of the male population is 59.1yrs and of the female 
population is 60.5 yrs. The overall mean age of the study population is 59.8 
yrs. 
 
 
  
2.RISK FACTORS: 
Table 2.1 : Risk Factors 
 
Cases Risk Factor 
No % 
a) Hypertension 
Present 
Absent 
 
65 
35 
 
65 
35 
b) DM 
    Present 
    Absent 
 
51 
49 
 
51 
49 
c) Smoking (among males) 
    Present 
    Absent 
 
34 
16 
 
68 
32 
d) CAD 
  Present 
 Absent 
 
32 
68 
 
32 
68 
e) Hyper lipid 
Present 
Absent 
 
34 
66 
 
34 
66 
f) Alcoholism 
(among males) 
Alcoholic 
Non Alcoholic 
Occasional Drinker 
 
 
16 
31 
3 
 
 
32 
62 
6 
  
 
  
• Hypertension constitutes the major risk factor in this stroke population 
as 65 % of the population is hypertensive. 34 males and 31 females are 
hypertensives and form 68 % and 62 % in their respective population. 
 
• Diabetes mellitus ranks second as a risk factor, constitute  51% of the 
study population with 23 (46 %) males and 28 (56 %) females. 
 
• Coronary Artery Disease is associated in 32 % of the population with 
15 (30 %) males and 17 (34 %) females.  
 
• 34 % of the stroke population has adverse lipid profile and both sexes 
share equal number of  hyperlipidemics ( 17 each ). 
 
• Among the male population, 34 (68 %) are smokers and 16 (32 %) are 
alcoholics.  
 
 
 
 
 
 
 
  
Table 2.2 : Risk Factors  according to sex 
 
Cases 
Males Females 
Risk Factor 
No. % No. % 
a) Hypertension 
Present 
Absent 
 
34 
16 
 
68 
32 
 
31 
19 
 
62 
38 
b) DM 
    Present 
    Absent 
 
23 
27 
 
46 
54 
 
28 
22 
 
56 
44 
c) Smoking (among males) 
    Present 
    Absent 
 
34 
16 
 
68 
32 
 
- 
50 
 
- 
100 
d) CAD 
  Present 
 Absent 
 
15 
35 
 
30 
70 
 
17 
33 
 
34 
66 
e) Hyper lipid 
Present 
Absent 
 
17 
33 
 
34 
66 
 
17 
33 
 
34 
66 
f) Alcoholism 
(among males) 
Alcoholic 
Non Alcoholic 
Occasional Drinker 
 
 
16 
31 
3 
 
 
32 
62 
6 
 
 
- 
50 
- 
 
 
- 
100 
- 
  
 
  
FIG 3  
URIC ACID DISTRIBUTION 
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3.Uric acid levels and their association with risk factors: 
The distribution of uric acid  levels in the study population are as 
under:  
¾ Less than 5 mg / dl – 49 % (25 males and 24 females ) 
¾ Between  5 – 6.9 mg / dl  -  26 % ( 13 males and 13 females ) 
¾ Above and equal to 7 mg / dl -  25 % (12 males and 13 females ). 
 
Table 3. A. : Uric Acid (mg/dl) 
 
Cases 
Males Females 
Uric Acid 
(mg/dl) No. % No. % 
Less than 5 25 50 24 48 
5 – 6.9 13 26 13 26 
7 & Above  12 24 13 26 
Total 50 100 50 100 
Mean 
S.D 
5.41 
1.88 
5.47 
1.53 
‘p’ 0.6586 
Not significant 
 
Mean uric acid level in males is 5.41 mg / dl and in females it is 5.47 
mg / dl. 
 
  
 
FIG 3.1.1 
AGE AND URIC ACID LEVELS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.36
4.98
5.49
7.07
6.6
3
3.5
4
4.5
5
5.5
6
6.5
7
7.5
U
R
IC
 A
C
ID
 L
EV
EL
S
40-49 50-59 60-69 70-79 80&above
  
3.1.AGE AND URIC ACID: 
            
Table 3.1.1 : Age and uric acid 
 
Uric Acid 
mg /dl 
Age group 
Mean S.D 
40 – 49 4.36 1.2 
50 – 59 4.98 1.47 
60 –69 5.49 1.5 
70 –79 7.07 1.7 
80 & above 6.6 2.14 
‘p’  0.0001 (Significant) 
 
 
Age wise distribution of uric acid is found statistically significant. As 
age advances the uric acid level also rises with the ‘P ‘value of 0.0001. This 
significance is maintained even when male and female populations are 
considered separately. (‘P ‘ of 0.0056 for males and 0.0077 for females). 
 
 
 
  
Table 3.1.2 : Age and uric acid according to sex 
 
Uric Acid 
Males Females 
Age group 
Mean S.D. Mean S.D. 
40 – 49 4.19 1.72 4.48 0.7 
50 – 59 5.0 1.54 4.92 1.3 
60 –69 5.42 1.53 5.54 1.51 
70 –79 7.1 2.1 7.04 1.45 
80 & above 8.4 - 4.8 0.85 
‘p’  0.0056 
Significant 
0.0077 
Significant 
 
 
The mean uric acid value for 40 – 49 yrs group is 4.36 mg /dl while the 
elderly age group of  above 70 yrs has the mean value 7.07 mg / dl. 
 
 
 
 
 
 
  
 
3.2 :  SEX AND URIC ACID :  
Table 3.2.1 : Sex and uric acid level 
 
Uric Acid (mg / dl ) Sex 
Mean S.D 
Males 5.41 1.88 
Females 5.47 1.53 
‘p’ 0.6586 (Not significant 
 
There is no statistically significant association is found in this study 
between sex and uric acid. The mean uric acid level among male population is 
5.41 mg / dl and among female population it is 5.47 mg / dl. 
  
3.3 HYPERTENSION AND URIC ACID: 
 
Table 3.3.1 : Hypertension and uric acid 
 
Uric Acid ( mg/ dl ) Hypertension 
Mean S.D 
Present 5.64 1.7 
Absent 5.06 1.68 
p 0.0793 (Not significant) 
 
            This study does not show any significant association between 
hypertension and uric acid. The mean uric acid level in hypertensive 
population is 5.64 mg / dl and in non hypertensive population is 5.06 mg/ dl. 
 
  
Table 3.3.2 : Hypertension and uric acid –sex wise 
 
Uric Acid (mg / dl ) 
Males Females 
Hypertension 
Mean S.D Mean S.D 
Present 5.49 1.76 5.82 1.64 
Absent 5.24 2.18 4.91 1.15 
p 0.3706 
Not Significant 
0.0763 
Not Significant 
 
         There is no significant association found, also when males and females 
are considered separately. The mean uric acid levels for male hypertensives is 
5.49 mg/ dl ( non hypertensive males- 5.24 mg / dl) and in females is 5.82 mg 
/dl (non hypertensive females – 4.91 mg / dl ). 
 
 
 
 
 
 
 
 
  
FIGURE 3.4 
DIABETES MELLITUS AND URIC ACID 
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3.4: DIABETES MELLITUS AND URIC ACID : 
                             
Table 3.4.1 : DM and uric acid 
 
Uric Acid ( mg / dl ) DM 
Mean S.D 
Present 5.98 1.66 
Absent 4.88 1.59 
p 0.0006 (Significant) 
 
There is a statistically significant association ( p value- 0. 0006) found 
between the level of uric acid and Diabetes mellitus. Among diabetics the 
mean uric acid value is 5.98 mg / dl while among non diabetics it is 4.88 mg / 
dl.  
                             
 
 
 
 
 
 
 
  
Table 3.4.2 : DM and uric acid according to sex 
 
Uric Acid ( mg / dl ) 
Males Females 
DM 
Mean S.D Mean S.D 
Present 6.16 1.86 5.83 1.49 
Absent 4.76 1.68 5.03 1.8 
p 0.0095 
Significant 
0.0525 
Not Significant 
 
 
This association is more significant among males ( p value -0.0006 ) 
among whom the diabetics have 6.16 mg / dl as mean uric acid level 
compared to non diabetics, 4.76 mg / dl as mean value.           
 
But, this association is not found significant in female population. The 
mean uric acid level in diabetic women is 5.83 mg / dl when compared to non 
diabetic women is 5.03 mg / dl . 
 
 
 
 
  
Fig 3.5.1 
CAD AND URIC ACID LEVELS 
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3.5 :CAD and Uric acid :  
 
Table 3.5.1 : CAD and Uric acid 
 
Uric Acid  (mg / dl )  CAD 
Mean S.D 
Present 6.46 1.87 
Absent 4.96 1.4 
p 0.0004 (Significant) 
  
          In this study,  mean uric acid level in this stroke population with CAD 
is 6.46 mgs / dl and in those without CAD is 4.96 mgs / dl and thus 
establishes a statistically significant relationship ( ‘p’ 0. 0004 ). 
 
  
Table 3.5.2 : CAD and Uric acid according to sex 
 
Uric Acid  (mg / dl ) 
Males Females 
CAD 
Mean S.D Mean S.D 
Present 6.98 1.72 5.99 1.93 
Absent 4.73 1.53 5.21 1.23 
p 0.0003 
Significant 
0.1659 
Not Significant 
 
           When males and females are considered, males have a significant 
association with a ‘p’ value of 0. 0003. Female population does not show such 
association. ( See table) 
 
 
 
 
 
 
 
 
 
  
3.6:Hyperlipidemia and uric acid : 
           
Table 3.6.1 : Hyperlipidemia and Uric acid 
 
Uric Acid (mg / dl ) Hyperlipidemia 
Mean S.D 
Present 5.75 1.9 
Absent 5.28 1.59 
p 0.2541 (Not significant) 
 
Mean uric acid level in hyperlipidemic stroke population is 5.75 mgs / 
dl and compared to 5.28 mgs / dl mean uric acid level in patients with out 
hyperlipidemia do not show any statistically significant relationship.  
 
  
  
Table 3.6.2 : Hyperlipidemia and Uric acid according to sex 
 
 
Uric Acid  (mg / dl ) 
Males Females 
Hyperlipidemia 
Mean S.D Mean S.D 
Present 5.67 2.16 5.84 1.67 
Absent 5.27 1.74 5.29 1.44 
p 0.7121 
Not significant 
0.3399 
Not significant 
 
There is no statistically significant relationship even when males and 
females are analysed separately. 
 
  
3.7 : Smoking and uric acid : 
            
Table 3.7.1 : Smoking and Uric acid 
 
Uric Acid  (mg / dl ) Smoking 
Mean S.D 
Present 5.14 1.8 
Absent 5.96 1.98 
p 0.0978 
Not significant 
  
Mean uric acid level in smokers is 5.14 mg / dl and among non-
smokers is 5.96 mgs / dl. Thus in this study there is no statistically significant 
relationship between smoking and uric acid. 
 
 
  
4. RISK FACTORS IN POPULATION WITH HIGH URIC ACID 
LEVEL ( ie.. > 7mgs / dl ) 
           
Table 4.1  : Risk Factors and uric acid levels < / > 7 mgs / dl 
 
Uric acid 
< 7mg/dl > 7mg/dl 
Risk Factor 
No. % No. % 
a) Hypertension 
Present 
Absent 
 
45 
30 
 
60 
40 
 
20 
5 
 
80 
20 
‘p’  0.1156 
Not significant 
b) DM 
    Present 
    Absent 
 
34 
41 
 
45.3 
54.7 
 
17 
8 
 
68 
32 
‘p’  0.0832 
Not significant 
c) Smoking (among males)(50) 
    Present 
    Absent 
 
27 
11 
 
71.1 
28.9 
 
7 
5 
 
58.3 
41.7 
‘p’  0.314 
Not significant 
d) CAD 
  Present 
 Absent 
 
15 
60 
 
20 
80 
 
17 
8 
 
68 
32 
‘p’ 0.0001 
Significant 
  
Uric acid 
< 7mg/dl > 7mg/dl 
Risk Factor 
No. % No. % 
e) Hyper lipid 
Present 
Absent 
 
22 
53 
 
29.3 
70.7 
 
12 
13 
 
48 
52 
‘p’  0.1436 
Not significant 
f) Alcoholism (among males) 
Alcoholic 
Non Alcoholic 
 
15 
23 
 
39.5 
60.5 
 
4 
8 
 
33.3 
66.7 
‘p’  0.6858 
Not significant 
No risk factor 
At least one risk factor 
7 
68 
9.3 
90.7 
2 
23 
8 
92 
‘p’ 0.6008 
Not significant 
Age 
>65 
<65 
 
11 
64 
 
42.3 
86.5 
 
15 
10 
 
57.7 
13.5 
‘p’ 0.0001 
Significant 
 
Further analysis is done to analyse the relationship between uric acid 
levels less than and more than 7 mgs / dl and the risk factors. This analysis 
shows age more than 65 yrs and CAD have statistically significant 
relationship with uric acid level. 
  
 
 
 
 
DISCUSSION 
 
  
DISCUSSION 
 
In this prospective study of 100 stroke population, males and females 
are equal in number (50 each ) and hence there is no sex bias. Further analysis 
shows the mean age, (males-59.1yrs, females-60.1 yrs ) and mean level of 
uric acid (males- 5.41mgs / dl, females- 5.47 mgs / dl ) are similar. 
Distribution of risk factors also is of in more or less similar pattern 
(Hypertension: males-34,females-31; Diabetes mellitus: males-23, females-
28; CAD: males-15 females-17 ; Hyperlipidemia ; males-17, females- 17). 
Different studies (9,12) show high mean uric acid level in male population 
which is not found in this study. 
 
But, in elderly population, both sexes show high level of uric acid 
which has statistical significance. Regarding the association between risk 
factors and both sexes, CAD is significantly associated with high uric acid 
levels in both sexes whereas DM is associated only with males and not with 
females. 
 
           In this study, most of the population belongs to anterior circulation 
territory, especially of middle cerebral artery region with commonest 
presentation being hemiplegia , except in one patient with bilateral cerebellar 
infarct evidenced in MRI scan. As most of the posterior circulation strokes 
  
have masquerading clinical presentations and often lack CT scan evidences of 
infarction, they are not included in this study to avoid inclusion bias. 
 
            Age is the most common non-modifiable risk factor for the 
development of stroke (14). In this study, 25 % of the population are above 65 
yrs with 12 males and 13 females. One pilot study (9) of 163 patients above 
70 yrs studied the association of SUA and stroke concludes that SUA is 
associated with an increased risk for acute ischaemic / nonembolic stroke in 
elderly patients independently of concurrent metabolic derangements. This 
study also shows evidences for a significant association between SUA and 
elderly stroke population, and the association was maintained even when both 
sexes are considered separately. Thus this study supports the association of 
high SUA and acute ischaemic / nonembolic stroke. 
 
Hypertension is the most common modifiable risk factor for stroke 
(14). SUA is also commonly associated with hypertension (65,66). Elevated 
SUA level is an independent predictor of  hypertension in 25 % of patients 
with new onset , untreated primary hypertension.(21). In this study, 
Hypertension constitutes the major risk factor as 65 % of the stroke 
population is hypertensive. The mean uric acid level of hypertensive 
population is 5.64 mgs / dl and of nonhypertensive is 5.06 mgs / dl and thus 
  
this study does not show any statistically significant relationship between 
SUA and hypertension. 
 
Diabetes mellitus ranks second as a risk factor in this study, constitute 
51 % of the study population. One population based study(6)involving 1017 
persons with NIDDM, concludes that hyperuricemia is a strong predictor of 
stroke events in middle aged persons with NIDDM, independently of other 
CV risk factors. SUA levels are often increased in subjects with MetS ( 47-
49). In this study, with the mean SUA level of 5.98 mgs / dl among diabetics 
and 4.88 mgs / dl among non-diabetics there is a  strong association between 
SUA and DM. Further analysis shows this association is more stronger among 
males (mean SUA in male diabetics -6.66 mgs / dl vs non-diabetic males- 
4.76 mgs / dl )than females. Thus this study strongly favours for an 
association between SUA and acute ischaemic / nonembolic stroke in diabetic 
population. 
 
SUA is significantly associated with cardiovascular mortality in certain 
epidemiological studies (13). One population based cohort study(67), with a 
follow up of 8.4 yrs, comprising 4385 participants of the Rotterdam study 
concludes that SUA is a strong risk factor for myocardial infarction and 
stroke. In this study CAD is found in 32 % of the patients with 15 males and 
17 females. The mean SUA level in this CAD population is 6.46 mgs / dl 
  
comparing this to patients without CAD is 4.96 mgs / dl which shows a strong 
statistical significance. Among those 32 stroke patients with CAD 17 have 
SUA > 7 mgs / dl. This also shows a strong statistical significance with a ‘p’ 
value of 0.0001. Hence this study strongly favours Rotterdam study and 
suggests SUA is a strong risk factor for myocardial infarction and stroke.  
 
Several prospective studies (69,70 ) have shown that higher levels of 
total cholesterol increase the risk of ischaemic stroke. Furthermore a meta-
analysis of 90000 patients (61) showed that administration of statins reduces 
the risk of stroke among patients with CAD and that this risk reduction is 
primarily related to the extent to which LDL-C levels are lowered. In some 
studies (71,72) relating Met S and SUA, increased SUA levels correlated with 
low HDL-C levels. 
 
                In our study, Hyperlipidemia is considered separately and not as a 
part of Met S. Moreover, most of our patients in this study population are 
from low socio-economic group and are not found obese. In this study, the 
mean uric acid level in hyperlipidemic patients is 5.75 mgs / dl and in patients 
without hyperlipidemia  is 5.28 mgs / dl and does not show any significant 
association between these variables. Out of 34 patients with hyperlipidemia in 
this study, only 12 are found to have SUA > 7 mgs / dl. 
 
 
  
Among the other risk factors like smoking and alcoholism, they are not 
considered as separate risk factors in many pilot studies of this kind. This 
study also fails to show any statistically significant relationship between SUA 
and these risk factors when considered separately.  
 
Further analysis between < 7 mgs / dl and > 7 mgs / dl SUA groups 
also maintain the association between high SUA and the risk factors namely 
age and CAD.  
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
CONCLUSION 
  
CONCLUSION 
 
1) This study shows that elevated SUA is strongly associated with an 
increased risk for the development of acute ischaemic/ non-embolic 
stroke in this study population. 
 
2) The association between elevated SUA and ischaemic stroke may need 
to be considered especially when treating elderly patients, diabetics 
and the population with coronary artery disease. 
 
3) Elevated SUA can be considered as one of the risk factors for acute 
ischaemic non-embolic stroke. 
 
4) Lowering of SUA level can be considered as one of the preventory 
modalities for stroke while treating high risk population. 
 
5) It is also suggested that further studies are required to assess whether 
lowering of SUA level with drugs can actually reduce the risk of 
ischaemic stroke. 
 
 
 
  
 
 
 
 
 
BIBLIOGRAPHY 
 
  
BIBLIOGRAPHY 
 
1. Adam and Victor’s principles of Neurology – 8th edition; Chapter 34; 
page 660-669 
2. Bonita R. Epidemiology of stroke. Lancet 1992; 339: 342–4. 
3. Buckley BM. Healthy ageing: ageing safely. Eur Heart J 2001; (Suppl. 
3): N6–10. 
4. Daskalopoulou SS, Athyros VG, Elisaf M, Mikhailidis DP. Uric acid 
levels and vascular disease. Curr Med Res Opin 2004; 20: 951–4. 
5. Fang J, Alderman MH. Serum uric acid and cardiovascular mortality. 
The NHANES I epidemiologic follow-up study, 1971–1992. JAMA 
2000; 283: 2404–10. 
6. Lehto S, Niscanen L, Ronnemaa T, Laasko M. Serum uric acid is a 
strong predictor of stroke in patients with non-insulin dependent 
diabetes mellitus. Stroke 1998; 29: 635–9.     
7. Weir CJ, Muir SW, Walters MR, Lees KR. Serum urate as an 
independent predictor of poor outcome and future vascular events after 
acute stroke. Stroke 2003; 34: 1951–6.    
8. Hoieggen A, Alderman MH, Kjeldsen SE et al., LIFE Study Group. 
The impact of serum uric acid on cardiovascular outcomes in the LIFE 
study. Kidney Int 2004; 65: 1041–9.   
9. Milionis HJ, Kalantzi KJ, Goudevenos JA, Seferiadis K, Mikhailidis 
DP, Elisaf MS. Serum uric acid levels and risk for acute ischaemic 
non-embolic stroke in elderly subjects. J Intern Med 2005; 258: 435 – 
441. 
  
10. Lehto S, Niscanen L, Ronnemaa T, Laasko M. Serum uric acid is a 
strong predictor of stroke in patients with non-insulin dependent 
diabetes mellitus. Stroke 1998; 29: 635–9. 
11. Rathmann W, Funkhouser E, Dyer AR, Roseman JM. Relations of 
hyperuricemia with the various components of the insulin resistance 
syndrome in young black and white adults: The CARDIA study 
[Coronary Artery Risk Development in Young Adults]. Ann Epidemiol 
1998; 8: 250 – 261. 
12. Waring WS. Uric acid: an important antioxidant in acute ischaemic 
stroke. Q J Med 2002; 95: 691–3. 
13. Fang J, Alderman MH. Serum uric acid and cardiovascular mortality. 
The NHANES I epidemiologic follow-up study, 1971–1992. JAMA 
2000; 283: 2404–10 
14. Epidemiology and stroke risk factors – office practice of Neurology 
,New York Churchill Livingstone 1996  pp 224-237 
15. Risk factors of stroke –Neurology Secrets 2nd edition pp-230 
16. uric acid and hyperuricemia –pages from e- medicine 
17. Jossa F, Farinaro E, Panico S et al. Serum uric acid and hypertension: 
the Olivetti Heart Study. J Hum Hypertens 1994; 8: 677–81. 
18. Sevanian A, Davies KJ, Hochstein P. Serum urate as an antioxidant for 
ascorbic acid. Am J Clin Nutr 1991; 54: 1129–34. 
19. Waring WS. Uric acid: an important antioxidant in acute ischaemic 
stroke. Q J Med 2002; 95: 691–3. 
20. DeFronzo RA, Ferranini E. Insulin resistance: a multifaceted syndrome 
responsible for NIDDM, obesity, hypertension, dyslipidemia, and 
atherosclerotic vascular disease. Diabetes Care. 1991;14:173–194 
  
21. Cannon PJ, Stason WB, Demartini FE, Sommers SC, Laragh JH. 
Hyperuricemia in primary and renal hypertension. N Engl J Med 1966; 
275: 457–464. 
22. Messerli FH, Frohlich ED, Dreslinski GR, Suarez DH, Aristimuno GG. 
Serum uric acid in essential hypertension: An indicator of renal 
vascular involvement. Ann Intern Med 1980; 93: 817– 821. 
23. Mazzali M, Hughes J, Kim YG, Jefferson JA, Kang DH, Gordon KL, 
et al. Elevated uric acid increases blood pressure in the rat by a novel 
crystal-independent mechanism. Hypertension 2001; 38: 1101 – 1106 
24. Watanabe S, Kang DH, Feng L, Nakagawa T, Kanellis J, Lan H, et al. 
Uric acid, hominoid evolution, and the pathogenesis of salt-sensitivity. 
Hypertension 2002; 40: 355– 360 
25. Kang DH, Nakagawa T, Feng L, Watanabe S, Han L, Mazzali M, et al. 
A role for uric acid in the progression of renal disease. J Am Soc 
Nephrol 2002; 13: 2888– 2897. 
26. Kanellis J, Watanabe S, Li JH, Kang DH, Li P, Nakagawa T, et al. Uric 
acid stimulates monocyte chemoattractant protein-1 production in 
vascular smooth muscle cells via mitogen-activated protein kinase and 
cyclooxygenase-2. Hypertension 2003; 41: 1287– 1293. 
27. Gu L, Okada Y, Clinton SK, Gerard C, Sukhova GK, Libby P, et al. 
Absence of monocyte chemoattractant protein-1 reduces 
atherosclerosis in low density lipoprotein receptor-deficient mice. Mol 
Cell 1998; 2: 275–281 
28. Love S. Oxidative stress in brain ischemia. Brain Pathol 1999; 9: 119– 
131 
29. Sun AY, Chen YM. Oxidative stress and neurodegenerative disorders. 
J Biomed Sci 1998; 5: 401– 414. 
  
30. Maxwell SR, Lip GY. Free radicals and antioxidants in cardiovascular 
disease. Br J Clin Pharmacol 1997; 44: 307– 317. 
31. Gariballa SE, Hutchin TP, Sinclair AJ. Antioxidant capacity after acute 
ischaemic stroke. Q J Med 2002; 95: 685– 690 
32. Spranger M, Krempien S, Schwab S, Donneberg S, Hacke W. 
Superoxide dismutase activity in serum of patients with acute cerebral 
ischemic injury: Correlation with clinical course and infarct size. 
Stroke 1997; 28: 2425– 2428. 
33. Leinonen JS, Ahonen JP, Lonnrot K, Jehkonen M, Dastidar P, Molnar 
G, et al. Low plasma antioxidant activity is associated with high lesion 
volume and neurological impairment in stroke. Stroke 2000; 31: 33– 
39. 
34. Squadrito GL, Cueto R, Splenser AE, Valavanidis A, Zhang H, Uppu 
RM, et al. Reaction of uric acid with peroxynitrite and implications for 
the mechanism of neuroprotection by uric acid. Arch Biochem Biophys 
2000; 376: 333– 337. 
35. Chamorro A, Obach V, Cervera A, Revilla M, Deulofeu R, Aponte JH. 
Prognostic significance of uric acid serum concentration in patients 
with acute ischemic stroke. Stroke 2002; 33: 1048– 1052 
36. Abuja PM. Ascorbate prevents prooxidant effects of urate in oxidation 
of human low density lipoprotein. FEBS Lett 1999; 446: 305 – 308 
37. Cherubini A, Polidori MC, Bregnocchi M, Pezzuto S, Cecchetti R, 
Ingegni T, et al. Antioxidant profile and early outcome in stroke 
patients. Stroke 2000; 31: 2295– 2300. 
38. Waring WS, Webb DJ, Maxwell SRJ. Effect of local hyperuricaemia 
on endothelial function in the human forearm vascular bed. Br J Clin 
Pharmacol 2000; 49: 511P. 
  
39. Bagnati M, Perugini C, Cau C, Bordone R, Albano E, Bellomo G. 
When and why a water-soluble antioxidant becomes pro-oxidant 
during copper-induced low-density lipoprotein oxidation: A study 
using uric acid. Biochem J 1999; 340: 143– 152 
40.  Boogaerts MA, Hammerschmidt DE, Roelant C, Verwilghen RL, 
Jacob HS. Mechanisms of vascular damage in gout and oxalosis: 
Crystal induced, granulocyte mediated, endothelial injury. Thromb 
Haemost 1983; 50: 576– 580. 
41. Duff GW, Atkins E, Malawista SE. The fever of gout: Urate crystals 
activate endogenous pyrogen production from human and rabbit 
mononuclear phagocytes. Trans Assoc Am Physicians 1983; 96: 234– 
245. 
42. Nakanishi N, Shiraishi T, Wada M. C-reactive protein concentration is 
more strongly related to metabolic syndrome in women than in men: 
The Minoh Study. Circ J 2005; 69: 386– 391 
43. Kondo N, Nomura M, Nakaya Y, Ito S, Ohguro T. Association of 
inflammatory marker and highly sensitive C-reactive protein with 
aerobic exercise capacity, maximum oxygen uptake and insulin 
resistance in healthy middle-aged volunteers. Circ J 2005; 69: 452 – 
457. 
44. Patetsios P, Rodino W, Wisselink W, Bryan D, Kirwin JD, Panetta TF. 
Identification of uric acid in aortic aneurysms and atherosclerotic 
artery. Ann NY Acad Sci 1996; 800: 243 – 245. 
45. Tsouli SG, Liberopoulos EN, Mikhailidis DP, Athyros VG, Elisaf MS. 
Elevated serum uric acid levels in metabolic syndrome: An active 
component or an innocent bystander? Metabolism 2006; 55: 1293– 
1301. 
  
46. Ishizaka N, Ishizaka Y, Toda EI, Nagai R, Yamakado M. Association 
between serum uric acid, metabolic syndrome, and carotid 
atherosclerosis in Japanese individuals. Arterioscler Thromb Vasc Biol 
2005; 25: 1038– 1044 
47. Schmidt MI, Duncan BB, Watson RL, Sharrett AR, Brancati FL, Heiss 
G. A metabolic syndrome in whites and African-Americans: The 
Atherosclerosis Risk in Communities baseline study. Diabetes Care 
1996; 19: 414 – 418. 
48. Yoo TW, Sung KC, Shin HS, Kim BJ, Kim BS, Kang JH, et al. 
Relationship between serum uric acid concentration and insulin 
resistance and metabolic syndrome. Circ J 2005; 69: 928 – 933. 
49. Athyros VG, Mikhailidis DP, Liberopoulos EN, Kakafika AI, 
Karagiannis A, Papageorgiou AA, et al. Effect of statin treatment on 
renal function and serum uric acid levels and their relation to vascular 
events in patients with coronary heart disease and metabolic syndrome: 
A subgroup analysis of the GREek Atorvastatin and Coronary heart 
disease Evaluation (GREACE) Study. Nephrol Dial Transplant 2007; 
22: 118 – 127. 
50. Modan M, Halkin H, Karasik A, Lusky A. Elevated serum uric acid: A 
facet of hyperinsulinaemia. Diabetologia 1987; 30: 713 – 718. 
51. Nakagawa T, Hu H, Zharikov S, Tuttle KR, Short RA, Glushakova O, 
et al. A causal role for uric acid in fructose-induced metabolic 
syndrome. Am J Physiol Renal Physiol 2006; 290: 625 – 631. 
52. Onat A, Uyarel H, Hergenc G, Karabulut A, Albayrak S, Sarı I, et al. 
Serum uric acid is a determinant of metabolic syndrome in a 
population- based study. Am J Hypertens 2006; 19: 1055– 1062 
  
53. Milionis HJ, Rizos E, Goudevenos J, Seferiadis K, Mikhailidis DP, 
Elisaf MS. Components of the metabolic syndrome and risk for 
firstever acute ischemic nonembolic stroke in elderly subjects. Stroke 
2005; 36: 1372– 1376. 
54. Kurl S, Laukkanen JA, Niskanen L, Laaksonen D, Sivenius J, 
Nyyssönen K, et al. Metabolic syndrome and the risk of stroke in 
middle-aged men. Stroke 2006; 37: 806 – 811 
55. Chen HJ, Bai CH, Yeh WT, Chiu HC, Pan WH. Influence of metabolic 
syndrome and general obesity on the risk of ischemic stroke. Stroke 
2006; 37: 1060– 1064 
56. Koren-Morag N, Goldbourt U, Tanne D. Relation between the 
metabolic syndrome and ischemic stroke or transient ischemic attack: 
A prospective cohort study in patients with atherosclerotic 
cardiovascular disease. Stroke 2005; 36: 1366– 1371. 
57. Expert Panel on Detection, Evaluation and Treatment of High Blood 
Cholesterol in Adults. Executive summary of the Third Report of the 
National Cholesterol Education Program (NCEP) Expert Panel on 
Detection, Evaluation, and Treatment of High Blood Cholesterol in 
Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486– 2497. 
58. Daskalopoulou SS, Tzovaras V, Mikhailidis DP, Elisaf M. Effect on 
serum uric acid levels of drugs prescribed for indications other than 
treating hyperuricaemia. Curr Pharm Des 2005; 11: 4161– 4175. 
59. Athyros VG, Elisaf M, Papageorgiou AA, Symeonidis AN, 
Pehlivanidis AN, Bouloukos VI, et al; GREACE Study Collaborative 
Group. Effect of statins versus untreated dyslipidemia on serum uric 
acid levels in patients with coronary heart disease: A subgroup analysis 
  
of the GREek Atorvastatin and Coronary-heart-disease Evaluation 
(GREACE) study. Am J Kidney Dis 2004; 43: 589 – 599. 
60. Athyros VG, Mikhailidis DP, Papageorgiou AA, Symeonidis AN, 
Pehlivanidis AN, Bouloukos VI, et al. The effect of statins versus 
untreated dyslipidaemia on renal function in patients with coronary 
heart disease: A subgroup analysis of the Greek atorvastatin and 
coronary heart disease evaluation (GREACE) study. J Clin Pathol 
2004; 57: 728 – 734. 
61. Amarenco P, Labreuche J, Lavallée P, Touboul P-J. Statins in stroke 
prevention and carotid atherosclerosis: Systematic review and 
metaanalysis. Stroke 2004; 35: 2902– 2909. 
62. Tayag EC, Nair SN, Wahhab S, Katsetos CD, Lighthall JW, Lehmann 
JC. Cerebral uric acid increases following experimental traumatic brain 
injury in rat. Brain Res1996; 733:287–91 
63. Kanemitsu H, Tamura A, Kirino T, Karasawa S, Sano K, Iwamoto T, 
Yoshiura M, Iriyama K. Xanthine and uric acid levels in rat brain 
following focal ischemia. J Neurochem1988; 51:1882–5  
64. Nieto FJ, Iribarren C, Gross MD, Comstock GW, Cutler RG. Uric acid 
and serum antioxidant capacity: a reaction to atherosclerosis? 
Atherosclerosis2000; 148:131–9 
65. Sundström J, Sullivan L, D’Agostino RB, Levy D, Kannel WB, Vasan 
RS. Relations of serum uric aid to longitudinal blood pressure tracking 
and hypertension incidence in the Framingham Heart Study. 
Hypertension 2005; 45: 28– 33. 
66. Masuo K, Kawaguchi H, Mikami H, Ogihara T, Tuck ML. Serum uric 
acid and plasma norepinephrine concentrations predict subsequent 
  
weight gain and blood pressure elevation. Hypertension 2003; 42: 
474–480 
67. Bos MJ, Koudstaal PJ, Hofman A, Witteman JC, Breteler MM. Uric 
acid is a risk factor for myocardial infarction and stroke: The 
Rotterdam study. Stroke 2006; 37: 1503– 1507. 
68. Cerebrovascular diseases – Harrison’s principles of Internal Medicine-
16th edition. Pages 2372-74. 
69. Zhang X, Patel A,Horibe H, Wu Z. Asia Pacific Cohort Studies 
Colloboration. Cholesterol, coronary artery disease and stroke in the 
Asia Pacific Region. Int J Epidemiol 2003; 32: 563-572. 
70. Horestein RB, Smith DE, Mosca L. Cholesterol predicts stroke 
mortality in the Women’s Pooling Project. Stroke 2002; 33c :1863-
1868. 
71. Astrios Kargiannis MD, Dimitri P. Mikhalidis MD, Konstantinos 
Tziomalos MD. Uric acid independently predicts early death after 
stroke. Circulation Journal 2007; 71 : 1120- 1127. 
72. Gain MP, Xue YM,Shan J, Zhou L. SUA in type 2 diabetic patients 
complicated by stroke.  Di Yi Jun Yi Da Xue Xue Bao 2002 ; Jan ; 
22(1) : 70- 71. 
 
 
 
 
 
 
  
 
 
 
 
 
APPENDIX I   - APPROVAL 
FROM ETHICAL 
COMMITTEE 
  
 
  
 
 
 
 
 
APPENDIX II – PROFORMA 
  
PROFORMA 
 
                                                         CASE NO 
 
Name:                                                                                                                                               
Age:                             Sex: M/F 
Address:                                                              
occupation:                         Income: 
 
Socioeconomic status:                                                    Handedness: R / L 
 
DOA:                                                          DOD:                      
 
PRESENT COMPLAINTS: 
 
 
H / O Present illness: 
         Duration-                          Seizures: Y / N        ICT Features; Y / N 
         H / O   LOC  : Y / N 
         S/O higher functions abnormality : 
        s/o cranial nerve lesions: 
        s/o motor system abnormalities: 
         s/o sensory involvement: 
  
          s/o cerebellar involvement:  
          s/o EPS involvement: 
 
PAST HISTORY 
          - HTN-Y/N    DM –Y/N    CAD-Y/N   CVA-Y/N   TIA-Y/N 
          GOUT-Y/N   Hyperlipidemia –Y/N 
 
PERSONAL HISTORY 
          SMOKING-                                   ALCOHOLISM 
           DIET- Veg/ Non veg/ mixed        DRUG INTAKE- Thiazide diuretic 
 
FAMILY HISTORY  
            DM-       ;HTN        ;CAD     ;TIA      ;CVA        ;GOUT        . 
 
CLINICAL EXAMINATION: 
      (a) VITALS: Pulse-     /mt;    BP-              mm of Hg 
     (b)Higher functions;        Consciousness; 
                                                    Memory          : 
                                                    Speech             : 
                                                    Behaviour    
      (c) Cranial nerves    ; 
(d) SPINOMOTOR SYSTEM:                                        R          L 
  
                                   1.Bulk of muscle          UL 
                                                                         LL 
                                   2.Tone                           UL 
                                                                          LL 
                                   3.Power                          UL 
                                                                          LL 
                                   4.DTR                            UL 
                                                                           LL 
                                   5.Plantar                           - 
(e) SENSORY SYSTEM 
(f) CEREBELLUM :  
 (g)  EPS                     : 
(h) SPINE / CRANIUM ;   
     
OTHER SYSTEMS ; 
         (a)   CVS               : 
         (b)    RS                : 
         (c)    P / A              ; 
 
                         DIAGNOSIS-    CVA –  Anterior circulation 
                                                                     Posterior circulation 
                                                                   Territory-  ACA   /    MCA 
  
INVESTIGATIONS : 
 
1.Blood    :  TC -                cells/cu.mm       2. Urine :        Alb – 
                      DC-  P     L      M     E      %                                  Sug- 
                     Hb-                   gms/dl                                       Dep- 
 
3.Blood :   Sugar-            mgs/dl         4. Lipid profile:TCL    mgs/dl 
                      Urea-                                                                        LDL 
                       Creatinine                                                               HDL 
                                                                                                       TGS 
5. SERUM URIC ACID- 
  
6.ECG  in all leads   -  
 
7.CT Brain Plain          - INFARCT   REGION  - 
                                            INFARCT   SIZE     - 
 
8.CARDIAC  EVALUATION -   
 
 
 
 
  
 
 
 
APPENDIX III- MASTER 
CHART 
MASTER CHART 
 
URIC ACID (MD/Dl) 
Sl.No AGE SEX HTN DM SMOKING CAD HYPER ALCOHOLISM DIET 
< 5 5 - 6.9 >7 
1 45 Male Absent Absent Yes Absent Present Occasional Mixed 3.4 - - 
2 80 Male Absent Absent Yes Absent Absent No Mixed - - 8.4 
3 48 Male Absent Absent Yes Absent Present Yes Mixed 2.6 - - 
4 51 Male Absent Absent Yes Absent Absent No Mixed 4.2 - - 
5 56 Male Present Present Yes Absent Present No Mixed - 6.2 - 
6 55 Female Absent Absent No Absent Absent No Mixed 4.3 - - 
7 78 Male Present Present No Present Absent No Mixed - - 8.1 
8 65 Female Absent Present No Present Present No Mixed 4.6 - - 
9 60 Male Present Absent No Absent Present No Mixed 4.5 - - 
10 62 Female Absent Absent No Absent Absent No Mixed 3.9 - - 
11 78 Female Absent Present No Absent Absent No Mixed - 5.4 - 
12 40 Female Absent Absent No Absent Absent No Mixed 4.2 - - 
13 65 Male Absent Present No Absent Absent No Mixed - 6 - 
14 50 Male Present Absent Yes Absent Absent No Mixed - 5.2 - 
15 52 Male Absent Absent Yes Absent Absent No Mixed 3.6 - - 
16 65 Female Present Present No Absent Absent No Mixed - 5.6 - 
17 65 Male Absent Present No Absent Absent Yes Mixed - 6.3 - 
18 50 Male Present Absent No Absent Absent No Mixed 4.2 - - 
19 75 Male Absent Present No Present Present No Mixed - - 8.4 
20 70 Female Present Absent No Present Absent No Mixed - - 7.5 
21 62 Male Present Present Yes Present Absent Yes Mixed - 6.3 - 
22 60 Female Present Absent No Absent Absent No Mixed 4.5 - - 
23 75 Female Absent Absent No Absent Absent No Mixed - - 7.2 
24 78 Male Present Present No Absent Absent No Mixed - 5.4 - 
25 48 Male Absent Absent No Absent Absent No Mixed 4 - - 
26 65 Female Present Present No Absent Absent No Mixed - - 7.2 
URIC ACID (MD/Dl) 
Sl.No AGE SEX HTN DM SMOKING CAD HYPER ALCOHOLISM DIET 
< 5 5 - 6.9 >7 
27 42 Female Absent Absent No Absent Present No Mixed 3.8 - - 
28 55 Male Absent Absent Yes Absent Absent No Mixed 3.9 - - 
29 61 Male Present Absent Yes Absent Absent No Mixed - 5.4 - 
30 53 Male Present Absent Yes Absent Absent Yes Non-Vege. 4.4 - - 
31 75 Male Present Absent Yes Absent Absent Yes Non-Vege. 4.2 - - 
32 47 Male Present Present Yes Absent Present Yes Non-Vege. - - 7.9 
33 58 Male Present Present No Present Present No Vege. - - 7.6 
34 70 Female Present Absent No Absent Absent No Non-Vege. - - 8.3 
35 55 Male Present Present No Present Absent No Non-Vege. - 5.2 - 
36 64 Female Present Present No Absent Absent No Non-Vege. - 3.9 - 
37 69 Female Present Present No Absent Present No Non-Vege. 4.8 - - 
38 40 Female Present Present No Present Absent No Non-Vege. 3.8 - - 
39 48 Female Present Absent No Absent Absent No Non-Vege. 4.2 - - 
40 84 Female Present Present No Present Absent No Vege. 4.2 - - 
41 40 Female Absent Present No Absent Absent No Non-Vege. - 5.6 - 
42 65 Male Present Absent No Absent Absent No Non-Vege. 4.7 - - 
43 70 Male Absent Absent No Absent Absent No Vege. - - 9.2 
44 65 Male Present Present Yes Absent Absent No Non-Vege. - 5 - 
45 50 Female Present Absent No Absent Absent No Non-Vege. 3.6 - - 
46 55 Male Present Present Yes Absent Absent No Non-Vege. 4.5 - - 
URIC ACID (MD/Dl) 
Sl.No AGE SEX HTN DM SMOKING CAD HYPER ALCOHOLISM DIET 
< 5 5 - 6.9 >7 
47 70 Female Present Present No Present Present No Vege. - - 9 
48 62 Female Present Absent No Absent Absent No Non-Vege. 4.4 - - 
49 73 Male Present Present No Absent Absent No Vege. - 5.2 - 
50 60 Male Present Absent Yes Present Absent Yes Non-Vege. - - 8.6 
51 40 Female Absent Absent No Absent Absent No Non-Vege. 3.7 - - 
52 47 Male Absent Present No Absent Present No Vege. 4.8 - - 
53 52 Male Present Absent Yes Absent Absent Yes Non-Vege. 4.2 - - 
54 62 Male Present Absent No Absent Absent Yes Non-Vege. 2.6 - - 
55 56 Male Absent Present Yes Present Present Yes Non-Vege. - - 8 
56 55 Male Present Absent Yes Present Absent Yes Non-Vege. - 6.3 - 
57 60 Female Present Absent No Present Absent No Non-Vege. - - 7.4 
58 60 Female Absent Present No Present Present No Non-Vege. - 6.8 - 
59 57 Male Present Absent Yes Absent Absent Yes Non-Vege. - 5.8 - 
60 53 Male Absent Absent Yes Absent Absent Yes Non-Vege. 2.8 - - 
61 42 Male Present Absent Yes Absent Present No Non-Vege. 4.4 - - 
62 58 Male Present Present Yes Absent Absent Yes Non-Vege. 3.8 - - 
63 75 Male Present Present No Present Absent No Vege. - - 9.2 
64 58 Male Present Present Yes Present Present No Non-Vege. - - 8.2 
65 65 Female Absent Present No Absent Absent No Non-Vege. - 5.8 - 
URIC ACID (MD/Dl) 
Sl.No AGE SEX HTN DM SMOKING CAD HYPER ALCOHOLISM DIET 
< 5 5 - 6.9 >7 
66 60 Female Present Present No Absent Present No Vege. - 6.2 - 
67 58 Female Present Present No Present Present No Vege. - - 7.4 
68 80 Female Present Absent No Absent Absent No Vege. - 5.4 - 
69 68 Female Present Present No Present Present No Non-Vege. - - 8.8 
70 55 Female Absent Present No Absent Present No Non-Vege. 4.6 - - 
71 62 Female Present Present No Present Present No Non-Vege. 3.8 - - 
72 45 Female Absent Absent No Absent Absent No Non-Vege. - 5.4 - 
73 45 Female Absent Present No Absent Present No Non-Vege. 4.2 - - 
74 68 Female Present Absent No Absent Absent No Non-Vege. 4.2 - - 
75 71 Female Present Present No Present Absent No Non-Vege. - - 7.2 
76 57 Male Present Present Yes Absent Absent Yes Non-Vege. 3.8 - - 
77 62 Female Present Present No Present Present No Non-Vege. - - 7 
78 48 Female Present Present No Present Absent No Non-Vege. 4.8 - - 
79 55 Female Present Absent No Absent Absent No Non-Vege. 4.6 - - 
80 50 Female Present Present No Present Present No Vege. - 5 - 
81 58 Male Present Absent Yes Absent Absent No Non-Vege. 3.8 - - 
82 49 Female Absent Present No Absent Present No Non-Vege. - 5.4 - 
83 64 Female Absent Present No Absent Absent No Non-Vege. - 6.6  
84 48 Female Absent Present No Absent Present No Non-Vege. 4.2 - - 
URIC ACID (MD/Dl) 
Sl.No AGE SEX HTN DM SMOKING CAD HYPER ALCOHOLISM DIET 
< 5 5 - 6.9 >7 
85 68 Female Present Present No Absent Present No Non-Vege. - - 7.2 
86 65 Female Absent Absent No Absent Absent No Non-Vege. 4.8 - - 
87 63 Male Present Present Yes Present Present Occasional Non-Vege. 3.8 - - 
88 65 Female Present Absent No Absent Absent No Non-Vege. - 5.2 - 
89 40 Male Absent Absent Yes Present Present No Non-Vege. 4 - - 
90 80 Male Present Present Yes Present Present Yes Non-Vege. - - 8.4 
91 50 Male Absent Absent Yes Absent Absent No Non-Vege. 4.2 - - 
92 47 Male Present Present Yes Absent Present No Non-Vege. 2.4 - - 
93 66 Female Absent Absent No Present Absent No Non-Vege. 2.8 - - 
94 72 Female Present Absent No Present Absent No Vege. 4.2 - - 
95 70 Female Present Absent No Absent Absent No Non-Vege. - - 7 
96 70 Female Present Present No Present Absent No Non-Vege. - - 7.6 
97 60 Female Present Present No Absent Present No Vege. - 6.4 - 
98 62 Male Present Present Yes Present Present No Non-Vege. - - 7.2 
99 60 Male Present Absent Yes Absent Present No Non-Vege. 4.6 - - 
100 68 Male Present Absent Yes Present Absent Occasional Non-Vege. - 5.4 - 
 
